HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ryuhei Okuyama Selected Research

Immune Checkpoint Inhibitors

3/2021Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation.
3/2021Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma.
1/2020Renin-Angiotensin System in the Tumor Microenvironment.
1/2018Involvement of local renin-angiotensin system in immunosuppression of tumor microenvironment.
1/2016Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma.
1/2016Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ryuhei Okuyama Research Topics

Disease

32Melanoma (Melanoma, Malignant)
11/2022 - 08/2004
18Neoplasms (Cancer)
11/2022 - 08/2004
8Neoplasm Metastasis (Metastasis)
11/2021 - 08/2004
4Psoriasis (Pustulosis Palmaris et Plantaris)
09/2021 - 03/2011
4Psoriatic Arthritis
01/2021 - 10/2016
4Inflammation (Inflammations)
03/2018 - 11/2005
3Infections
09/2020 - 01/2006
3Atopic Dermatitis (Atopic Eczema)
10/2019 - 11/2012
3Mycosis Fungoides
01/2017 - 01/2006
3Wounds and Injuries (Trauma)
07/2015 - 03/2006
2Leg Ulcer
12/2021 - 01/2011
2Hypersensitivity (Allergy)
10/2019 - 01/2017
2Vasculitis (Vasculitides)
02/2018 - 08/2013
2Basal Cell Carcinoma (Rodent Ulcer)
03/2016 - 06/2014
2Pyogenic Granuloma
03/2016 - 09/2010
1Stevens-Johnson Syndrome (Lyell's Syndrome)
01/2022
1Rheumatoid Vasculitis
12/2021
1Systemic Lupus Erythematosus (Libman-Sacks Disease)
09/2021
1Hypohidrosis
04/2021
1Circulating Neoplastic Cells
03/2021
1Brain Neoplasms (Brain Tumor)
03/2021
1Sacroiliitis
01/2021
1Spondylitis
01/2021
1Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome)
12/2020
1Extramammary Paget Disease (Paget Disease, Extramammary)
11/2020
1Ankylosing Spondylitis
01/2020
1Dermatitis
10/2019
1Thymoma (Thymic Carcinoma)
06/2019
1Porphyria Cutanea Tarda
01/2019
1Type 1 Diabetes Mellitus (Autoimmune Diabetes)
10/2018
1Colonic Neoplasms (Colon Cancer)
01/2018

Drug/Important Bio-Agent (IBA)

9NivolumabIBA
11/2022 - 01/2016
7Biomarkers (Surrogate Marker)IBA
11/2022 - 10/2016
6Proteins (Proteins, Gene)FDA Link
11/2022 - 11/2005
6Immune Checkpoint InhibitorsIBA
03/2021 - 01/2016
5LigandsIBA
11/2022 - 01/2014
5AntibodiesIBA
07/2021 - 01/2016
4DNA (Deoxyribonucleic Acid)IBA
11/2019 - 10/2016
4IpilimumabIBA
11/2019 - 12/2012
4AntigensIBA
02/2018 - 12/2012
3pembrolizumabIBA
11/2022 - 06/2016
3Therapeutic UsesIBA
11/2022 - 11/2005
3Paclitaxel (Taxol)FDA LinkGeneric
11/2020 - 12/2013
3Cell-Free Nucleic AcidsIBA
03/2020 - 01/2016
3InterleukinsIBA
01/2018 - 04/2009
2CytokinesIBA
11/2022 - 07/2015
2Pharmaceutical PreparationsIBA
11/2022 - 03/2021
2SteroidsIBA
01/2022 - 01/2006
2Neoplasm Antigens (Tumor Antigens)IBA
07/2021 - 01/2018
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
03/2021 - 01/2014
2Melanins (Melanin)IBA
02/2021 - 01/2021
2Adalimumab (Humira)FDA Link
01/2021 - 01/2020
2ErbB Receptors (EGF Receptor)IBA
11/2020 - 04/2016
2CysteinyldopaIBA
01/2020 - 11/2018
2Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA
10/2019 - 01/2017
2Nerve Growth Factors (Neurotrophins)IBA
10/2019 - 01/2017
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2018 - 08/2010
2Immunoglobulin E (IgE)IBA
09/2016 - 11/2005
25-hydroxymethylcytosineIBA
05/2016 - 02/2014
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
04/2016 - 04/2009
2Immunoglobulin G (IgG)IBA
11/2014 - 04/2009
2LipopolysaccharidesIBA
01/2014 - 04/2009
2Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
08/2010 - 06/2006
2Adenosine Triphosphate (ATP)IBA
05/2010 - 04/2009
2CPG-oligonucleotideIBA
11/2005 - 08/2004
2OligodeoxyribonucleotidesIBA
11/2005 - 08/2004
1Programmed Cell Death 1 ReceptorIBA
11/2022
1ChemokinesIBA
11/2022
1Etanercept (Enbrel)FDA Link
01/2022
1apalutamideIBA
01/2022
1Certolizumab PegolFDA Link
12/2021
1Tissue Inhibitor of Metalloproteinase-3IBA
11/2021
1Cysteine (L-Cysteine)FDA Link
11/2021
1Hydroxychloroquine (Plaquenil)FDA LinkGeneric
09/2021
1Angiotensin Receptors (Angiotensin II Receptor)IBA
07/2021
1Carbonic Anhydrase IIIBA
04/2021
1LipidsIBA
03/2021
1Fatty Acid-Binding Protein 7IBA
03/2021
1CateninsIBA
03/2021
1Cyclosporine (Ciclosporin)FDA LinkGeneric
12/2020
1Trastuzumab (Herceptin)FDA Link
11/2020
1human ERBB2 proteinIBA
11/2020
1Voriconazole (Vfend)FDA LinkGeneric
09/2020
1Type 1 Angiotensin ReceptorIBA
01/2020
1C-Reactive ProteinIBA
01/2020
1Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA
01/2020
1Immunoglobulins (Immunoglobulin)IBA
06/2019
1Antiviral Agents (Antivirals)IBA
01/2019
1Acyclovir (Aciclovir)FDA LinkGeneric
09/2018
1Antimicrobial PeptidesIBA
03/2018
1CathelicidinsIBA
03/2018
1Antineutrophil Cytoplasmic Antibodies (ANCA)IBA
02/2018
1B7-H1 AntigenIBA
01/2018
1Angiotensin Receptor AntagonistsIBA
01/2018
1ArginaseIBA
01/2018

Therapy/Procedure

26Therapeutics
11/2022 - 08/2004
7Immunotherapy
01/2020 - 11/2005
3Molecular Targeted Therapy
03/2021 - 11/2012
2Combination Drug Therapy (Combination Chemotherapy)
11/2020 - 12/2013
1Transplantation
09/2018